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Objective: To quantify the structural characteristics and nanomechanical properties of aggrecan produced
by adult bone marrow stromal cells (BMSCs) in peptide hydrogel scaffolds and compare to aggrecan from
adult articular cartilage.
Design: Adult equine BMSCs were encapsulated in 3D-peptide hydrogels and cultured for 21 days with
TGF-b1 to induce chondrogenic differentiation. BMSC-aggrecan was extracted and compared with
aggrecan from age-matched adult equine articular cartilage. Single molecules of aggrecan were visual-
ized by atomic force microcopy-based imaging and aggrecan nanomechanical stiffness was quantiﬁed by
high resolution force microscopy. Population-averaged measures of aggrecan hydrodynamic size, core
protein structures and CS sulfation compositions were determined by size-exclusion chromatography,
Western analysis, and ﬂuorescence-assisted carbohydrate electrophoresis (FACE).
Results: BMSC-aggrecan was primarily full-length while cartilage-aggrecan had many fragments. Single
molecule measurements showed that core protein and GAG chains of BMSC-aggrecan were markedly
longer than those of cartilage-aggrecan. Comparing full-length aggrecan of both species, BMSC-aggrecan
had longer GAG chains, while the core protein trace lengths were similar. FACE analysis detected aw1:1
ratio of chondroitin-4-sulfate to chondroitin-6-sulfate in BMSC-GAG, a phenotype consistent with
aggrecan from skeletally-immature cartilage. The nanomechanical stiffness of BMSC-aggrecan was
demonstrably greater than that of cartilage-aggrecan at the same total sGAG (ﬁxed charge) density.
Conclusions: The higher proportion of full-length monomers, longer GAG chains and greater stiffness of
the BMSC-aggrecan makes it biomechanically superior to adult cartilage-aggrecan. Aggrecan stiffness
was not solely dependent on ﬁxed charge density, but also on GAG molecular ultrastructure. These
results support the use of adult BMSCs for cell-based cartilage repair.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Tissue engineering substitutes have great potential for the
restoration of the biological function of damaged and diseased
cartilage1, which has limited intrinsic self-regeneration capabilities.
Approaches to cartilage tissue engineering involve numerous
design considerations involving cell source (e.g., chondrocytes,
synoviocytes, marrow/adipose-derived progenitor cells),to: C. Ortiz, Department of
s Institute of Technology,
s Research Society International. Pbiocompatible scaffold chemistry and morphology, bioactive
signaling factors that promote cellular differentiation, maturation,
and extracellular matrix (ECM) synthesis, mechanical stimulation,
gene therapy, microenvironmental factors and bioreactors2. While
many tissue engineering methodologies produce cartilage-like
neo-tissues with similar macromolecular components compared to
the native cartilage ECM, a major challenge is to produce constructs
having biochemical, structural and biomechanical properties that
are functionally equivalent to cartilage in vivo3.
The overall composition and organization of neocartilage are
typically characterized via biochemical4,5, histological and immu-
nohistochemical6 measures, while ECM molecular constituents
have been analyzed using various chromatographic7 and electro-
phoretic techniques8,9. Tissue-level biomechanical measurementsublished by Elsevier Ltd. All rights reserved.
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neocartilage are related to and ultimately determined by the
macromolecular constituents and assembly of the ECM12,13.
Recently, high resolution imaging and nanomechanical methodol-
ogies have been developed to directly visualize the detailed intra-
molecular structure and probe the nanoscale mechanical
properties of various ECM constituents (e.g., aggrecan14,15,
collagen16,17, hyaluronan18). These techniques provide an under-
standing of molecule-to-molecule variability, intramolecular and
local nanoscale properties, and the ability to assess properties of
selected sub-populations that cannot be revealed by macroscopic
measures which provide population averages. The combination of
new nanotechnological approaches with traditional biochemical,
histological, and macroscopic mechanical methods, can greatly
assist in understanding, evaluating and optimizing a proposed
tissue-engineered strategy.
Because aggrecan is the dominant compressive load-bearing
macromolecule in cartilage ECM19, its expression, synthesis, organi-
zation, and turnoverareoftenusedasbiomarkersof thechondrogenic
potentialofbonemarrowstromalcells (BMSCs) incell-basedcartilage
tissue engineering20e22. Recent studies showed that the sulfated
glycosaminoglycan (sGAG) content of BMSC-seeded agarose and self-
assembling peptide hydrogels was lower than that in parallel
hydrogels seeded with chondrocytes from skeletally-immature
cartilage20,23, and varied with scaffold material23,24. Aggrecan accu-
mulated within BMSC-seeded constructs was structurally different
from that in native cartilage or in similar hydrogels seeded with
chondrocytes. In agarose, BMSC-synthesized aggrecanwas shown by
Western analysis to be primarily full-length22; in the peptide gel,
atomic forcemicroscopy (AFM) imaging showed that BMSC-aggrecan
had longer core protein and larger GAG chain length23. The chon-
drogenic potential of adult human BMSCs was found to be indepen-
dent of age orosteoarthritis (OA)25, an advantage of using BMSCs over
chondrocytes for autologous cell-based cartilage repair26 for older OA
patients, where the source and capacity of chondrocytes are limited.
Given these advantages of BMSC-based cartilage repair, rigorous
molecular-level characterizationofBMSC-producedECMisneeded to
further understand adult BMSC chondrogenesis.
The goal of this study was to investigate aggrecan produced by
adult equine BMSCs encapsulated in peptide hydrogels and induced
to undergo chondrogenic differentiation and to compare with
aggrecan extracted from age-matched adult equine articular carti-
lage. The detailed molecular structure and properties of aggrecan
were quantitatively assessed using high resolution AFM-based
approaches. First, the ultrastructure of these two aggrecan pop-
ulations was investigated via AFM-based single molecule imaging.
Secondly, the aggrecan-GAG sulfation patterns and extent of core
protein proteolysis were characterized using ﬂuorescence-assisted
carbohydrate electrophoresis (FACE)8, Western blot, and size-
exclusion chromatography analyses. Finally the nanomechanical
properties of these two aggrecan populations were evaluated using
high resolution force microscopy. Adult BMSC-peptide aggrecan
demonstrated ultrastructural features and GAG sulfation similar to
those of skeletally-immature (young) cartilage-aggrecan, and had
increased compressive stiffness compared to adult cartilage-
aggrecan.
Methods
Tissue harvest
Cartilage tissue was harvested aseptically from the femo-
ropatellar groove, and bone marrow was harvested from three
skeletally-mature (2e5-year-old adults) mixed-breed horses as
described previously23. Horses were euthanized at Colorado StateUniversity for reasons unrelated to this study, and for conditions
that would not affect either cartilage or bone marrow.
Marrow stromal cell isolation
BMSCs were isolated and stored as previously described23.
Marrow samples were washed in phosphate buffered saline (PBS)
and fractionated by centrifugation to separate the nucleated cells
from the red blood cells. BMSCs were isolated by differential
adhesion to tissue culture plastic. After BMSC colonies reached local
conﬂuence, cells were detached and reseeded at 6103 cells/cm2,
expanded to w3104 cells/cm2 over 3 days, and cryo-preserved.
Before hydrogel encapsulation, BMSCs were thawed and plated at
6103 cells/cm2. After 3 days, cells were detached (passage-1) and
reseeded at 6103 cells/cm2, and expanded for 3 days prior to
encapsulation in peptide hydrogels.
Hydrogel encapsulation and culture
KLD12 peptide with the sequence AcN-(KLDL)3-CNH2 was
synthesized by the MIT Biopolymers Laboratory (Cambridge, MA)
using an ABI Model 433A peptide synthesizer with Fluorenyl-
methyloxycarbonyl chloride (FMOC) protection. BMSCs were
encapsulated in 0.35% (w/v) KLD12 peptide at a concentration of
10106 cells/ml using acellular agarose casting molds to initiate
peptide assembly as described previously23. BMSC-seeded disks
(6.35 mm-diam 1.6 mm-thick) were cultured in high glucose
Dulbecco's Modiﬁed Eagle Medium (DMEM) (Invitrogen, Carlsbad,
CA) supplemented with 1% ITSþ1 (ﬁnal concentration: 10 mg/ml
insulin, 5.5 mg/ml transferrin, 5 ng/ml sodium selenite, 0.5 mg/ml
bovine serum albumin, 4.7 mg/ml linoleic acid, SigmaeAldrich),
0.1 mM dexamethasone (SigmaeAldrich, St. Louis, MO), 37.5 mg/ml
ascorbate-2-phosphate (Wako Chemicals, Richmond, VA), 1% PSA,
10 mM HEPES, 400 mM L-proline, 1 mM sodium pyruvate, and 1%
Non-essential amino acids (NEAA), with 10 ng/ml rhTGF-b1
(R&D Systems, Minneapolis, MN) with medium changes every 2e3
days. Disks were cultured for 21 days.
Aggrecan extraction
Aggrecan was extracted from BMSC-peptide gels and native
articular cartilage [Fig. 1(a)] with 4 M guanidine HCl, 100 mM
sodium acetate, pH 6.8, containing Protease Complete inhibitor mix
(Roche, Indianapolis, IN) for 48 h at 4C with agitation27. Extracts
were adjusted to 1.58 g/ml by the addition of CsCl and centrifuga-
tion at 470,000gav for 72 h at 4C. The D1 fractions (>1.54 g/ml)
were desalted by dialysis against water, dried and used for AFM
imaging, nanomechanical testing, and Western analysis. Unfrac-
tionated GuHCl extracts were also desalted and used for FACE
analysis8.
AFM imaging
D1 aggrecan samples at 50 mg sGAG/ml in MilliQ water were
deposited on 3-aminopropyltriethoxysilane (APTES; SigmaeAldrich,
St. Louis,MO) functionalizedmuscovitemica substrates (SPI Supplies,
West Chester, PA) and rinsed with MilliQ water after 30 min, as
previously described14. Electrostatic interactions between the posi-
tively charged APTES-mica and the negatively charged GAG chains
retained aggrecan on the surface in a relatively ﬂat conformation14,
despite rinsing in water. Tapping mode imaging [Fig. 1(b)] was per-
formed in ambient conditionswith a Nanoscope IIIaMultimode AFM
(Veeco Instruments, Plainview, NY) and Super Sharp Silicon AFM
probes (nominal cantilever spring constant¼ 42 N/m, nominal tip
end radius <5 nm; Nanosensors, Switzerland). A thin layer
Fig. 1. (a). Aggrecanwas extracted from adult equine BMSC-peptide gels (after 21 days of culture) and from adult equine articular cartilage. The model of full-length aggrecan shows
the globular domain structures labelled as G1, G2, G3, linked by a core protein substituted with keratan sulfate (KS) and, chondroitin sulfate (CS). (b) An illustration of aggrecan
imaging using AFM tapping mode. Aggrecan molecules were immobilized on the APTES-modiﬁed mica substrate in a ﬂattened conformation and imaged by a sharp silicon probe
tip. (c) Illustrations of AFM nanomechanical testing. Microcontact-printed aggrecan patterns were surrounded by self-assembled monolayer molecules (11-mercaptoundecanol, HS
(CH2)11OH, OH-SAM). A spherical gold-coated glass tip (functionalized with OH-SAM) was used to scan and compress the aggrecan patterns. The experiment was performed in
0.001e1.0 M NaCl (pHw5.6). (d) Height-normal force measurement: contact mode imaging was used to apply a range of normal compressive forces while scanning across the
patterned surface to measure the compressed height H of aggrecan. (e) Normal forceedistance measurements: direct compression of aggrecan was performed by having the probe
tip approach the surface perpendicular to the plane of the substrate and measuring the force as a function of tip-to-substrate distance D.
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conditions28 which partially hydrates the aggrecan.
Quantiﬁcation of aggrecan single molecule dimensions
AFM height images were digitized into pixels and aggrecan
structural features (i.e., core protein and GAG trace length) were
traced and calculated automatically with a customMatlab program
(The MathWorks, Natick, MA) or manually with SigmaScan Pro
image analysis software (SPSS Science, Chicago, IL). Full-length
aggrecan were identiﬁed quantitatively by the presence of G1 and
G3 domains having increased height (>0.5 nm) at the ends of the
core protein.
Aggrecan nanomechanical testing
Microcontact printing29 was employed to produce micrometer-
sized hexagonally-patterned surfaces of densely packed, chemically
end-grafted aggrecan surrounded by a neutral hydroxyl-termi-
nated self-assembled monolayer (11-mercaptoundecanol, HS
(CH2)11OH, OH-SAM)15 [Fig. 1(c)]. A Multimode picoforce Nano-
scope IV AFM (Veeco Instruments, Plainview, NY) was used to
perform compressive nanomechanical testing with an OH-func-
tionalized spherical colloidal probe tip15 (cantilever spring constant
w0.12 N/m, tip end radius w2.5 mm; Novascan, Ames, IA). Two
measurements were employed to assess the mechanical stiffness of
the aggrecan. First, the absolute compressed height H of aggrecan
as a function of applied normal force was obtained by scanning
parallel to the substrate surface and across the hexagon region15
[Fig. 1(d)] using contact mode imaging over a wide range of
normal forces (0w30 nN), and in aqueous solutions of 0.001e1 M
NaCl (pHw5.6). Secondly, normal compression of aggrecan was
performed by having the probe tip approach perpendicularly to the
substrate [z-piezo displacement velocity¼ 2 mm/s, Fig. 1(e)]. Raw
data were converted to normal force as a function of tip-to-
substrate distance, D as described previously15. Do is deﬁned as theD where the force ﬁrst increases above noise level. Normal stress
was calculated from the normal force using the surface element
integration method15,30. The total sGAG content within a hexagon
on the gold substrate was measured by dimethylmethylene blue
dye assay (DMMB)4 after testing. The initial sGAG density prior to
compression, calculated by dividing the sGAG content by pattern
volume, was w20 mg/ml (one aggrecan molecule per
w25 nm 25 nm) at 0.1 M NaCl for both BMSC-peptide and carti-
lage-extracted aggrecan samples. sGAG density during compres-
sion was calculated as a function of compressed height by
normalizing the total sGAG content under the probe tip to the
reduced compressed volume. (This estimate of density assumes
minimal outward “bulging” of aggrecan at the radial periphery of
the layer under the tip. Since the tip diameter (2R)>>Do and, given
the lateral constraint of the adjacent uncompressed aggrecan, this
assumption is reasonably well justiﬁed.)
Core protein heterogeneity
Aggrecan core protein heterogeneity was analyzed by Western
blotting. Samples were treated with protease-free chondroitinase
ABC (30 mU/100 mg GAG), keratanase II (0.5 mU/100 mg GAG) and
endo-b-galactosidase (0.5 mU/100 mg GAG) (Seikagaku, Tokyo,
Japan) and digests corresponding to 10 mg GAG were loaded on
4e15% polyacrylamide gels and probed with antibodies to the
aggrecan G1 (JSCATEG)31.
Relative hydrodynamic sizes of aggrecan and GAG
Sephacryl S-1000 and Superose 6 Fast protein liquid chroma-
tography (FPLC) chromatography (GE Healthcare, Piscataway, NJ)
were used to characterize the hydrodynamic size distributions of
aggrecanmonomers and their constituent GAG chains, respectively.
Aggrecan (200 mg sGAG) was eluted on S-1000 at 30 ml/h with
0.5 M sodium acetate at pH 6.8. For GAG analysis, 100 mg aggrecan
was digested with 50 mg proteinase K in 200 ml ammonium acetate
H.-Y. Lee et al. / Osteoarthritis and Cartilage 18 (2010) 1477e14861480(pH 7.2) for 48 h at 60C and 100 ml of the digest was eluted on
Superose 6. Fractions (0.5 ml) were collected at 0.5 ml/min and
assayed for sGAG by DMMB. The void volume Vo and total volume Vt
were determined using 0.5 mm polystyrene beads and phenol red,
respectively. The partition coefﬁcient (Kav) was estimated as
(Ve Vo)/(Vt Vo), for each eluted fraction Ve.
FACE analysis of GAG sulfation
FACE analysis was performed on proteinase K digests of BMSC-
peptide aggrecan from three different adult horses and cartilage-
extracted aggrecan from one adult horse. Samples containing
2e10 mg of sGAG were digested with chondroitinase ABC, disac-
charide products ﬂuorotagged by reductive amination with
2-aminoacrodone, prior to separation and quantitation by FACE8.
Statistical analyses
Aggrecan and GAG molecular dimensions are reported as
mean SD in text and in ﬁgures for population distribution. For
data-sets having a unimodal distribution, a Gaussian ﬁt was used to
test for normality, and the goodness of ﬁt was evaluated by R2 (the
summed mean squares of the regression divided by the summed
mean squares of the data). For normally distributed data-sets,
two-tailed, unpaired Student t tests were performed to test for
differences of the means, with signiﬁcance set at P< 0.05. For non-
unimodal distributions, a two-sample KolmogoroveSmirnov (KeS)Fig. 2. AFM height images of aggrecan monomers. (a)e(c) Aggrecan produced by adult equ
articular cartilage. In (a) and (d), the globular domains of full-length aggrecan are indicated
asterisks in (d). Examples of core protein and GAG chain traces are shown in (b).test was performed to compare distributions of molecular dimen-
sions. For comparison between groups, 95% conﬁdence intervals
were used.
Results
Single molecule ultrastructure of BMSC-peptide and native
cartilage-aggrecan
AFM height images compare the ultrastructure of BMSC-peptide
aggrecan [Fig. 2(aec)] to cartilage-extracted aggrecan [Fig. 2(def)].
Individual aggrecan molecules were directly visualized and the
details of their intramolecular structure including the core protein
and constituent GAG chains were identiﬁed [Fig. 2(b), (c), (e) and
(f)]. In many cases, the brighter globular domains (G1, G3) at the
ends of the core protein [arrows in Fig. 2(a) and (d)] could be
identiﬁed by their increased height (>0.5 nm) relative to the rest of
the molecule. Aggrecan with globular domains at both N (G1)- and
C (G3) termini were identiﬁed as “full-length”, i.e., those which had
not been enzymatically cleaved along the core protein32,33. The
molecular dimensions of the aggrecan from the two sources were
strikingly different. The BMSC-peptide aggrecan had noticeably
longer GAG chains than cartilage-extracted aggrecan [Fig. 2(b) and
(c) vs Fig. 2(e) and (f), quantiﬁed below]. Moreover, short fragments
[Fig. 2(d), asterisks] were more pronounced in the cartilage-
extracted aggrecan population than in BMSC-peptide aggrecan
(quantiﬁed below).ine BMSCs seeded in peptide hydrogel. (d)e(f) Aggrecan extracted from adult equine
by arrows. Examples of short degraded aggrecan fragments (w100 nm) are marked by
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The distributions of the core protein trace length for the BMSC-
peptide and cartilage-extracted aggrecan were markedly different
[KeS test, P< 0.0001, Fig. 3(a) and (b)], with BMSC-peptide
aggrecan¼ 440138 nm (mean SD) and cartilage-extracted
aggrecan¼ 220142 nm. While the length distributions were
broad and nearly bimodal [Fig. 3(a) and (b)], the constituent sub-
populations of full-length aggrecan [Fig. 2(c) and (d)] were both
normally distributed with peaks at 487 nm and 475 nm that were
not signiﬁcantly different from each other (P¼ 0.32). A large
proportion (w40%) of the BMSC-peptide aggrecan was full-length
[Fig. 3(a) and (c)], whereas the majority of the cartilage-aggrecan
(w86%) was fragments [Fig. 3(b) and (d)] consistent with proteo-
lytic degradation. Full-length cartilage-extracted aggrecan
comprised a smaller sample size [n¼ 20, Fig. 3(d)] due to the lower
proportion of full-length aggrecan observed in the whole pop-
ulation. The difference in size of themolecular populations was also
seen in the S-1000 chromatograms [Fig. 3(e)]: BMSC-peptide
aggrecan eluted earlier (Kav¼ 0.25) than the cartilage-extracted
aggrecan (Kav¼ 0.42), consistent with the larger average hydrody-
namic size of BMSC-peptide aggrecan.
Western analyses were performed on the same samples to
further assess the heterogeneity of the core protein constituents by
using antibodies against the G1 domain of the core proteins. The
BMSC-peptide aggrecan showed a greater abundance of high-Fig. 3. Core protein analyses. Core protein trace length distributions of (a) BMSC-peptide a
(Mean SD is noted in each histogram. n¼ number of measured aggrecan molecules.) The d
test, P< 0.0001). Core protein trace length distributions of full-length (c) BMSC-peptide aggre
the goodness of ﬁt R2 is 0.997 and 0.974 in (c) and (d), respectively. These two core protein le
(e) Elution proﬁles of BMSC-peptide and cartilage-extracted aggrecan on a Sephacryl S-1000
aggrecan, indicating the greater hydrodynamic size of BMSC-peptide aggrecan. (f) Western b
molecular weight core fragment species (*) were detected in both BMSC-peptide and cartilmolecular-weight species reacting with anti-G1 antibody, consis-
tent with a larger population of full-length aggrecan [Fig. 3(f)]. The
major G1-immunoreactive fragment seen in both the BMSC-
peptide and cartilage-extracted aggrecan samples was similar to
the molecular weight of a previously characterized calpain33-
generated “double-globe” species (w120 kDa). In addition, the
G1-containing bands between 56 and 101 kDa suggest that carti-
lage-aggrecan may have undergone more extensive proteolysis
than the BMSC-aggrecan. However, it may be difﬁcult to assess the
total extent of proteolysis from this technique as such fragments
could remain in lower density fractions and be less well recovered.
GAG chain length and sulfation
The distribution of individual GAG chain lengths within a single
representative full-length aggrecan in the BMSC and cartilage
populations of Fig. 3(c) and (d) is shown in Fig. 4(a) and (b),
respectively. The selected full-length BMSC-peptide aggrecan has
longer average GAG length [47 8 nm, n¼ 41 chains, Fig. 4(a)] than
that of the single cartilage-aggrecan [17 7 nm, n¼ 44 chains,
Fig. 4(b)]. The GAG chains of this BMSC-peptide aggrecan also have
a broader length distribution than that of the cartilage-extracted
aggrecan [Fig. 4(a) and (b)]. For multiple aggrecan molecules, GAG
chain lengths were measured and an average chain length per
molecule was calculated [Fig. 4(c) and (d)]. The mean of the average
GAG length per molecule was 4410 nm for BMSC-aggrecanggrecan and (b) cartilage-extracted aggrecan measured from the AFM height images.
istributions of the two core protein populations (a and b) are markedly different (KeS
can and (d) cartilage-extracted aggrecan. Gaussian curves were ﬁt to both distributions;
ngth distributions (c and d) are not signiﬁcantly different (two-tailed t test, P¼ 0.3531.)
column. Kav¼ 0.25 for the BMSC-peptide aggrecan and 0.42 for the cartilage-extracted
lot analysis with anti-G1 antibody. High-molecular-weight core protein as well as low
age-extracted aggrecan samples.
Fig. 4. GAG chain length and composition analysis. Distribution of GAG trace lengths on one selected single representative (a) BMSC-peptide aggrecan and (b) cartilage-extracted
full-length aggrecan. Mean SD is noted in each histogram. n¼ number of measured GAG chains. Distribution of average GAG chain lengths for multiple (c) BMSC-peptide aggrecan
and (d) cartilage-extracted aggrecan. n¼ number of measured aggrecan molecules. Distribution of average GAG chain length on multiple full-length (e) BMSC-peptide aggrecan and
(f) cartilage-extracted aggrecan. n¼ number of measured aggrecan molecules. The goodness of the Gaussian ﬁt R2 in (c)e(f) is 0.971, 0.968, 0.901 and 0.999, respectively. (g)
Superose 6 chromatography shows the BMSC-peptide GAG population is longer than the cartilage-extracted GAG population with Kav¼ 0.50 and 0.71, respectively. (h) FACE analysis
of aggrecan produced by BMSCs derived from three adult horses and that of aggrecan extracted from adult cartilage. The BMSC-peptide aggrecan showed an approximately equal
amount of DDi6S and DDi4S in contrast to the increased DDi6S content of cartilage-extracted aggrecan.
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Fig. 4(d)]. The n (number of measured aggrecan molecules) in Fig. 4
(d) was smaller than that in Fig. 3(b) because some fragments did
not have detectable GAG chains. For the full-length aggrecan pop-
ulations of Fig. 3(c) and (d), the corresponding GAG trace length of
BMSC-peptide aggrecan was about twice as long as that of
cartilage-aggrecan [Fig. 4(e) and (f)]. For both “all observed” [Fig. 4
(c) and (d)] and “full-length” [Fig. 4(e) and (f)] aggrecan pop-
ulations, the mean GAG chain length per aggrecan molecule of the
BMSC-peptide aggrecan was signiﬁcantly longer than that of
cartilage-extracted aggrecan (P< 0.0001). For each population
(BMSC-peptide or cartilage-extract), the “all observed” and “full-
length” aggrecans had similar GAG lengths (P¼ 0.175 and 0.642,
respectively).
The relative hydrodynamic size of BMSC- and cartilage-aggrecan
GAG chains was also assessed by Superose 6 size-exclusion chro-
matography [Fig. 3(g)]. The BMSC-aggrecan GAGs eluted at
Kav¼ 0.50 while cartilage-extracted GAGs eluted at Kav¼ 0.71, cor-
responding to average chain lengths ofw60 disaccharides (27 kDa,
corresponding tow60 nm contour length) andw30 disaccharides
(13 kDa, w30 nm), respectively34, assuming the proteinase K used
here and the papain digestion used previously34 generated single
chondroitin sulfate (CS) chain.FACE analyses showed that aggrecan CS chains produced by
peptide-encapsulated BMSCs from three adult equines were
composed of approximately equimolar amounts of 4- and 6-
sulfated disaccharides, a ratio characteristic of skeletally-immature
and growing cartilage. In contrast, the adult cartilage-extracted
aggrecan showed a higher proportion of 6-sulfated disaccharides,
typical of adult cartilage35.
Aggrecan compressive stiffness
The three-dimensional AFM height images of microcontact-
printed substrates veriﬁed the presence of clear hexagonal patterns
of both BMSC-peptide and cartilage-extracted aggrecans [Fig. 5(a)
and (b)]. Consistent with previous results15, the aggrecan height, H,
decreased monotonically with increasing ionic strength and with
increasing normal force during a lateral scan and reached the ﬁnal
incompressible height by w30 nN force [Fig. 5(c) and (d)]. The
initial heights at low force reﬂect the relative differences in lengths
of the two aggrecan populations observed via AFM imaging. At any
given ionic strength, the BMSC-peptide aggrecan pattern showed
w2e3 fold longer initial height than cartilage-aggrecan.
In the one-dimensional forceedistance measurements [Fig. 5(e)
and (f)], normal force increased markedly with compression
Fig. 5. Nanomechanical testing. AFM three-dimensional height images of (a) BMSC-peptide and (b) cartilage-extracted aggrecan chemically end-grafted on gold substrates and
patterned by microcontact printing. The images were taken in 0.001 M NaCl with a minimal applied normal forcew100 pN. Compressed aggrecan height H vs normal force curves
of (c) BMSC-peptide and (d) cartilage-extracted aggrecan in different ionic strength aqueous solutions were measured by contact mode AFM. Insert in (d) shows the direction of the
scan and the corresponding compressed height H. Each data point represents the average aggrecan height from eight scans across the pattern at a given normal force and NaCl
concentration. The standard deviation (SD) of each data point is smaller than the size of the data point. Normal force vs distance curves of (e) BMSC-peptide and (f) cartilage-
extracted aggrecan during normal compression as shown in the insert in (f). The probe tip approaches the substrate perpendicular to the plane of the substrate. Each curve is an
average of 30 approaches in different locations on the pattern. The SD of each averaged curve is smaller than the line width. (g) Comparison of the height-normal force
measurement (open triangles, replotted from c and d, 0.01 M NaCl) and normal forceedistance measurements (lines, replotted from e and f, 0.01 M NaCl). Data measured using two
different methods well coincide. Some slight discrepancy at low normal force (<5 nN) is possibly due to the ﬁnite normal force necessary for maintaining stable feedback during the
contact mode scanning.
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At any given ionic strength, the BMSC-peptide aggrecan exerted
a repulsive force against tip at longer Do (e.g., Dow600 nm) for
BMSC-peptide aggrecan and w200 nm for cartilage-aggrecan in
0.001 M NaCl [Fig. 5(e) and (f)], reﬂecting the larger initial height
and stronger electrostatic repulsion interactions of BMSC-peptide
aggrecan. The compressive properties studied with these two
different nanomechanical methodologies, heighteforce and
forceedistance, coincide well with each other [Fig. 5(g)]. The small
difference between H and D at low force (<5 nN) was likely due to
the tare force (w100 pN) necessary to enable stable feedback
during imaging15.
Finally, to directly compare the compressive stiffness of the two
aggrecan populations independent of their different initial heights(i.e., core protein lengths), the forceedistance curves of Fig. 5(e) and
(f) were converted to stress vs DMMD-measured sGAG concentra-
tion (see Methods). At physiological ionic strength (0.1 M NaCl), the
normal stress increased markedly with increasing compression
(i.e., density of compressed GAG), but much more dramatically for
the BMSC-peptide aggrecan (Fig. 6).
Discussion
This study of aggrecan macromolecules from tissue-engineered
constructs and native cartilage involved the combination of high
resolution AFM-based techniques to quantify nanoscale structure
and nanomechanical properties. Such an approach can provide
a platform for optimization of cell source, scaffold and culture
Fig. 6. StressesGAG concentration curves converted from the forceedistance curves in
Fig. 5(e) and (f) (0.1 M NaCl). The initial uncompressed sGAG concentration was the
total sGAG amount measured by DMMB divided by the aggrecan pattern volume
measured by AFM height images. Normal stress was calculated from the force using
the surface element integration method30. Upon compression by the probe tip, the
sGAG density of the end-grafted aggrecan under the probe tip increased due to the
decrease in compressed volume. When both aggrecan patterns were compressed to
the same sGAG concentration, BMSC-peptide aggrecan exhibited greater stress than
the cartilage-extracted aggrecan (note: GAG concentration in native tissue is
20e80 mg/ml)46. Each curve is an average of 30 approaches in different locations on
the aggrecan pattern. The 95% conﬁdence intervals of each averaged curve are smaller
than the line width.
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and their inter- and intramolecular heterogeneity. Marked differ-
ences were observed between adult BMSC- and cartilage-aggrecan
populations. BMSC-aggrecan was predominantly full-length with
fewer proteolytically degraded fragments andmuch longer CS-GAG
chains than cartilage-aggrecan. These detailed AFM-based
measurements were consistent with size-exclusion chromatog-
raphy and Western analyses. In addition, AFM nanomechanical
measurements showed that the compressive stiffness of the BMSC-
aggrecan was markedly higher than that of cartilage-aggrecan.
Taken together, these results suggest that adult BMSC-aggrecan
exhibits characteristics more similar to those of skeletally-imma-
ture growth cartilage than to adult cartilage.
Imaging of single molecules revealed that aggrecan synthe-
sized by adult BMSCs in peptide hydrogel had an overall
morphology qualitatively similar to that in adult cartilage, con-
sisting of a GAG-functionalized core protein19. However, the two
aggrecan populations had strikingly different molecular dimen-
sions (Figs. 2 and 3). Based on AFM imaging, 50% of the BMSC-
aggrecan had a core protein length >400 nm, compared to only
16% of the cartilage-aggrecan [Fig. 3(a) and (b)]. S-1000 chroma-
tography demonstrated average molecular sizes that were
consistent with AFM-based results. Western analyses suggested
that the major G1-immunoreactive constituents of cartilage-
aggrecan were fragments which have been previously shown to
be generated by aggrecanases32 (G1-NITEGE) and m-calpain33
(G1eG2eGVA), though the action of other proteinases cannot be
excluded. In contrast, BMSC-peptide aggrecan was predominantly
full-length, typical of aggrecan from immature cartilage14,36. The
activity of aggrecan proteolytic enzymes is known to be regulated
by TGF-b, but evidence exists for both inhibition37 and upregu-
lation38 of proteolysis. Interestingly, if compared to the aggrecan
produced by adult articular chondrocytes under the identical
conditions with TGF-b stimulation23, the adult BMSC-aggrecan
have a larger proportion of full-length core proteins than the adult
chondrocyte-aggrecan. The full-length BMSC- and cartilage-
aggrecan had similar core protein trace lengths exhibitinga Gaussian distribution [Fig. 3(c) and (d)]. Together, these results
suggest that the decreased average core protein trace length seen
in the entire cartilage-aggrecan population was due to proteolytic
degradation.
The GAG chains of BMSC-aggrecan were found to be more than
two times longer than that of cartilage-aggrecan (Fig. 4). CS chain
length has been shown to decrease with age in cartilage tissue27,39
and is also smaller when synthesized by adult chondrocytes
cultured in vitro, reﬂecting an age dependent alteration of aggre-
can-GAG synthesis40. Longer GAGs are prevalent in aggrecan from
immature cartilage39,41, growth plate34 and newly synthesized
aggrecan after injury42, as well as during the early stages of OA43.
The latter two studies hypothesized that the increased CS chain
length in injured and OA-cartilage was indicative of growth carti-
lage metabolic phenotype. The CS sulfation ﬁne structure analyses
are also consistent with such a conclusion. The sulfation patterns of
CS-GAGs analyzed by FACE have been studied previously as
a characteristic of animal age, GAG chain termination, tissue
differentiation and development41,44,45. Adult BMSCs synthesized
CS with w1:1 DDi6S-to-DDi4S ratio, similar to that observed
previously in skeletally-immature and growing cartilage34,35, while
adult cartilage contained aggrecan predominantly with 6S-sulfated
CS [Fig. 4(h)], consistent with previous studies35. The differences in
the GAG structure between the two aggrecan populations in this
study suggest that adult BMSCs undergoing chondrogenesis in
peptide hydrogels exhibit a very different pattern of glycosylation
than adult chondrocytes in native tissue.
The exact mechanisms whereby cells control CS chain length
and sulfation pattern are still under study. TGF-b has been shown to
affect CS-GAG synthesis; for example, TGF-b-stimulated ﬁbroblasts
produced elongated CS-GAG chains. In our recent study23 in which
animal-matched articular chondrocytes and BMSCs from immature
or adult equines were cultured under identical conditions for 3
weeks in the same peptide hydrogel and in the same (TGF-b1-
containing) medium, the BMSCs produced longer GAG chains than
the animal-matched chondrocytes. This observation suggests that
longer GAG chains are not just a result of TGF-b stimulation, but
also a reﬂection of cell type. Since the GAGs contribute to the
stiffness of cartilage, and proteolytic loss of protein-bound GAGs is
a major characteristic of OA, the BMSC-aggrecan would appear to
have a more favorable GAG structure for cartilage mechanical
function than the adult cartilage-aggrecan.
Amajor ﬁnding in the present studywas the demonstration that
BMSC-aggrecan was demonstrably stiffer in nanomechanical
compression than cartilage-aggrecan. The BMSC-aggrecan pop-
ulation had a larger average core protein length; thus, its pattern
height [Fig. 5(c) and (d)] and tip-substrate separation distancewere
larger than that of cartilage-aggrecan at the same normal force and
ionic strength [Fig. 5(e) and (h)]. In order to compare their intrinsic
stiffness independent of aggrecan dimensions, the forceedistance
curves were converted to curves of stress vs DMMB-measured
sGAG concentration (Fig. 6). Upon compression by the AFM tip,
which increased sGAG concentration under the tip, the BMSC-
aggrecan exhibited larger compressive stress. The macroscopic
compressive moduli of bulk cartilage are known to correlate well
with the concentration of speciﬁc ECM constituents12,46 such as
collagen and GAG; and the correlationwith GAG is ascribed to sGAG
ﬁxed charge density46. However, our observation indicates that at
the nanoscale, not only the constituent sGAG charge density, but the
molecular structure and dimensions of the GAGs can affect
compressive stiffness. The longer CS chains of BMSC-aggrecan may
result in more intermolecular entanglement, steric and stronger
excluded volume effects during deformation. In addition, electro-
static interactions between highly charged, closely-spaced rod-like
chains are known to cause higher and more nonlinear increases in
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spatially homogeneous densities of ﬁxed charge15,47. These
phenomena may be particularly important in localized regions
such as the microenvironment of cells, e.g., the pericellular matrix,
which can be stimulated by mechanical forces. It also suggested
that the stiffer BMSC-produced constructs in comparison with the
chondrocyte-produced constructs we reported previously23 may
not only due to the more total matrix content of the BMSC
construct, but also due to the longer GAG chain and core protein
length of BMSC-aggrecan. The greater stiffness of BMSC-aggrecan
is also an attribute of immature native aggrecan48 and may be
advantageous to cartilage repair.
Taken together, the nanomechanical properties of adult BMSC-
peptide aggrecan appear superior to that of adult native cartilage-
aggrecan. Adult BMSCs are thus a promising cell candidate for
cell-based tissue engineering for cartilage repair and regeneration.
Of course, additional challenges must be met to achieve successful
cartilage repair in vivo, including the assembly of an appropriate
collagen architecture and the synthesis and assembly of other
matrix macromolecules to enable integrationwith the surrounding
tissues. The combined methodologies utilized here can be applied
to optimize the cell source and culture for engineering desired ECM
assemblies. The detailed structure and nanomechanical properties
of aggrecan and other ECM molecules can provide insights into the
molecular determinants to the integrity and functionality of
cartilage repair.
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